For Institutions
About
Fosun Pharma plans to invest USD198.8 million to acquire a 51% stake in Green Valley Shanghai Pharmaceuticals, known for its Alzheimer's drug GV-971. Shares fell after the announcement. Fosun aims to enhance its central nervous system treatment portfolio and support clinical trials for GV-971. Green Valley faced production halts due to regulatory issues, posting a net loss of USD9.6 million. The acquisition is seen as a strategic move to improve Fosun's market position in CNS treatments.
Fosun Pharma Industrial is acquiring a majority stake in an Alzheimer's drug developer for RMB1.27 billion. The deal includes purchasing 8.6667% equity from Shiyin Investment and Shibirun for RMB143 million, and subscribing to new capital for a 46.3504% stake. A special purpose vehicle will be formed with a 51% stake held by Fosun Pharma. The acquisition aims to enhance Fosun Pharma's market position and advance Alzheimer's treatment development.
